Immetas Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11M

  • Investors
  • 1

Immetas General Information

Description

Developer of novel therapeutics designed to modulate the innate immune system to treat age-related cancer and inflammatory diseases. The company's approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases and is anchored in clinical evidence to mitigate development risk, enabling healthcare professionals to treat age-related cancer and osteoarthritis.

Contact Information

Website
www.immetas.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 120 Eagle Rock Avenue
  • Suite 141
  • East Hanover, NJ 07936
  • United States
+1 (973)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 120 Eagle Rock Avenue
  • Suite 141
  • East Hanover, NJ 07936
  • United States
+1 (973)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immetas Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 23-Sep-2020 $11M Completed Generating Revenue
To view Immetas’s complete valuation and funding history, request access »

Immetas Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to modulate the innate immune system to treat age-related cancer and inflammato
Drug Discovery
East Hanover, NJ

Schlieren, Switzerland
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immetas Competitors (3)

One of Immetas’s 3 competitors is ImmunOs Therapeutics, a Venture Capital-Backed company based in Schlieren, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland
Palleon Pharmaceuticals Venture Capital-Backed Waltham, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 3 of 3 competitors. Get the full list »

Immetas Patents

Immetas Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022072697-A2 Bispecific binding molecules 2 Inactive 30-Sep-2020
WO-2022072697-A3 Bispecific binding molecules 2 Inactive 30-Sep-2020
AU-2020252191-A1 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein Inactive 01-Apr-2019
CA-3135838-A1 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein Pending 01-Apr-2019
EP-3947449-A1 Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein Inactive 01-Apr-2019 C07K16/2818
To view Immetas’s complete patent history, request access »

Immetas Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Morningside Group Venture Capital Minority
To view Immetas’s complete investors history, request access »

Immetas FAQs

  • When was Immetas founded?

    Immetas was founded in 2018.

  • Where is Immetas headquartered?

    Immetas is headquartered in East Hanover, NJ.

  • What industry is Immetas in?

    Immetas’s primary industry is Drug Discovery.

  • Is Immetas a private or public company?

    Immetas is a Private company.

  • What is Immetas’s current revenue?

    The current revenue for Immetas is .

  • How much funding has Immetas raised over time?

    Immetas has raised $11M.

  • Who are Immetas’s investors?

    Morningside Group has invested in Immetas.

  • Who are Immetas’s competitors?

    ImmunOs Therapeutics, Palleon Pharmaceuticals, and Intellia Therapeutics are competitors of Immetas.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process